Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last.”
More posts featuring Tom Powles on OncoDaily.